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Palma, Beatriz Duarte, Alexandre Gabriel, Jr., Fernando A. B.
Colugnati, and Sergio Tufik. Effects of sleep deprivation on the
development of autoimmune disease in an experimental model of
systemic lupus erythematosus. Am J Physiol Regul Integr Comp
Physiol 291: R1527–R1532, 2006. First published June 29, 2006;
doi:10.1152/ajpregu.00186.2006.—Sleep is hypothesized to play a
restorative role on immune system. In addition, disturbed sleep is
thought to impair host defense mechanisms. Chronic sleep deprivation
is a common occurrence in modern society and has been observed in
a number of chronic inflammatory conditions, such as systemic lupus
erythematosus (SLE). New Zealand Black/New Zealand White (NZB/
NZW) F1 mice develop an autoimmune disease that strongly resem-
bles SLE in humans, exhibiting high titers of antinuclear antibodies
associated with the development of rapidly progressive and lethal
glomerulonephritis. On the basis of this evidence, the present study
examined the onset and progress of lupus in as-yet healthy female
mice submitted to sleep deprivation. Sleep deprivation was accom-
plished by two 96-h periods in the multiple-platform method when
mice were 10 wk old, and they were observed until 28 wk of age.
Blood samples were collected from the orbital plexus fortnightly to
evaluate serum antinuclear antibodies and anti-double-stranded DNA.
Proteinuria and longevity as well as body weight were also assessed.
The results indicated that mice submitted to sleep deprivation exhib-
ited an earlier onset of the disease, as reflected by the increased
number of antinuclear antibodies. However, no statistical difference
was found in the other parameters analyzed. According to these
results, sleep deprivation could be considered as a risk factor for the
onset but not for the evolution of the disease.
sleep; New Zealand Black/New Zealand White F1 mice; antinuclear
antibody
INCREASING EVIDENCE suggests a bidirectional communication
between sleep and the immune system. On one hand, mediators
of the immune response regulate physiological sleep, both at
normal and exacerbated function, which can be observed
during infection (for reviews, see Refs. 2 and 34). On the other
hand, sleep is hypothesized to have a restorative function on
immune processes. On the basis of results from a study (13) in
which sleep deprivation (SD) caused the invasion of normally
sterile body tissues by pathogenic bacteria, it may considered
that abnormalities of host defense including immune suppres-
sion would render healthy sleep-deprived individuals suscep-
tible to disease. However, these relationships have not been
studied extensively.
The hypothesis that sleep might influence host defenses has
been suggested by the association between decreased sleep
time and increased morbidity and mortality in humans (21, 61)
and by the findings in rats that SD results in septicemia and
eventually death (13). SD affects several other facets of the
immune system, including antigen uptake (6), phagocytosis
(37), mitogen responses (32), antibody responses (23, 49), and
a variety of lymphocyte subsets (9).
The effects of SD on the immune system have been widely
studied. This is an important issue in its own right because SD
is becoming a more frequent and more accepted occurrence in
modern society. In addition, sleep disorders have been ob-
served in a number of chronic inflammatory conditions, such as
autoimmune diseases. Some of these clinical states associated
with sleep disturbances include rheumatoid arthritis, fibromy-
algia, and systemic lupus erythematosus (SLE) (for a review,
see Ref. 24). The sleep disruption that is observed in some of
the immune and autoimmune disorders is most likely the result
of dysregulations of the sleep-immune system relationship than
merely a discomfort induced by the disease symptoms or
manifestations, such as pain.
SLE is an autoimmune disease primarily affecting young
women at reproductive age. The female-to-male incidence
ratio is approximately 9:1 in most series (43). The preponder-
ance of SLE in women may result, in part, from stimulation of
the immune system by female hormones (28). This chronic
inflammatory disease is characterized by the formation of
autoantibodies and deposition of immune complexes, resulting
in glomerulonephritis and vasculitis. In SLE, one of the dom-
inant antibodies is directed against the cell nucleus: antinuclear
antibodies (ANA). Estrogen, pregnancy, stress, and intake of a
variety of drugs are associated with the onset and worsening of
SLE (19, 35, 39, 42). Lupus patients complain of unrefreshing
sleep and daytime fatigue, which results from sleep distur-
bances (8, 27, 53, 54, 56). According to Valencia-Flores and
colleagues (56), these patients are sleepier during the day by
virtue of sleep fragmentation due to more arousals and stage
transitions. In addition, the disease is exacerbated by sleep
disruption, resulting in decreased sleep efficiency and delta
sleep.
New Zealand Black/New Zealand White (NZB/NZW) F1
mice spontaneously develop an autoimmune disease that
closely resembles immunological and clinical characteristics of
human SLE. The evolution of the disease is characterized by
abnormal polyclonal B cell activation with a high production of
ANA that includes anti-double-stranded DNA (anti-DNA),
lymphadenopathy, arthritis, hemolytic anemia, vasculitis, and a
variety of histopathological manifestations, of which glomer-
ulonephritis is the most prominent (55). Also, similar to char-
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acteristics in humans, the disease is most frequent in female
mice, and the susceptibility is influenced by the major histo-
compatibity complex (57).
Although a large number of studies have focused on the
relationship between the immune system and SD, relatively
few have examined the long-term effects of SD and/or have
evaluated more than one postdeprivation recovery day to de-
termine the time course of postdeprivation changes in immu-
nological parameters. If one considers that increased sleep
fragmentation and increased disease activity and pain sensitiv-
ity are common features of SLE patients, it is clearly necessary
to investigate experimental paradigms that allow a more pre-
cise understanding of the impact of SD on autoimmune dis-
ease. To determine whether SD can precipitate or exacerbate
the development of autoimmunity in genetically predisposed
animals, the disease course in NZB/NZW F1 mice was as-
sessed by following the development of ANA, proteinuria, and
longevity.
MATERIALS AND METHODS
Animals and experimental procedures. All procedures were carried
out in accordance with the guidelines on animal care of the National
Institutes of Health and were approved by the Animal Care and Use
Committee of the Universidade Federal de Sa˜o Paulo (CEP No.
1163/01).
NZB (females) and NZW (males) mice were obtained from the
Universidade de Sa˜o Paulo (Sa˜o Paulo, Brazil) and were mated in our
Research Laboratory to produce NZB/NZW F1 hybrids. After being
weaned, NZB/NZW F1 mice were housed in groups of six in plastic
cages filled with hardwood bedding and provided water and rodent
chow ad libitum. Animals were kept in a room with controlled lighting
(12:12-h light-dark cycle) and temperature (24 2°C). Because of the
fact that murine lupus is more prevalent in females, only this gender
was used in the present study. In addition, both control nondeprived
and SD female mice were age matched because there is a natural
age-dependent evolution of the disease.
SD procedures. Female NZB/NZW F1 mice aged 10 wk (an age in
which they are clinically healthy) were subjected to SD using an
adaptation of the multiple-platform method originally developed for
rats (52). The technique is based on the muscle atonia that accompa-
nies paradoxical sleep (18). Briefly, 12 narrow circular platforms (3
cm in diameter) were placed inside a tiled tank (41  34  17 cm)
filled with water to within 1 cm below the upper border of the
platform. Groups of six animals were placed on the platforms in each
tank, an arrangement that allowed them to move inside the tank,
jumping from one platform to the other. In this procedure, animals are
aroused from sleep when the loss of muscle tone leads them to fall off
the platform. This method produces a consistent amount of sleep
reduction in mice (47).
Animals were randomly distributed into two groups: control mice,
which remained in their home cages in the SD room (n 22); and SD
mice, which were deprived of sleep for two periods of 96 h each with
an interval of 3 days (n 28). This experimental protocol was carried
out as an attempt to simulate a chronic condition of SD (similar to
what is observed in chronic inflammatory disease). During the inter-
val, animals were placed back in their home cages. Throughout the
study, both groups had free access to food and water. After the end of
SD, animals in the experimental group were placed back in their home
cages, and both groups were observed for several weeks.
Blood sampling procedures and ANA determination. At 10 (before
SD), 13, 16, 19, 22, 25, and 28 wk of age, mice were weighed, rapidly
anesthetized (ether vapors), and bled from the orbital venous plexus
with the use of plain capillary tubes (41). After being centrifuged, the
serum was separated and stored at 20°C until analysis.
Determination of ANA and anti-DNA. ANA was determined by a
standard indirect immunofluorescence (IIF) technique using HEp-2
cells as the substrate (Kallestad, Bio-Rad Laboratories, Redmond,
WA). IIF on HEp-2 cells remains the method of choice for ANA
detection (48). In the case of negative ANA, the diagnosis of SLE is
very unlikely. The manufacturer’s protocol was followed. Briefly,
autoantibodies in a test sample bound to antigens in the substrate. A
wash with PBS removed the excess serum from the substrate. Fluo-
rescein-conjugated (FITC) antiserum added to the substrate attached
to the bound autoantibody. FITC-conjugated rabbit antibodies against
mice IgG were kindly donated by Biolab. In these procedures, a
fluorescent antibody served as the marker for the antigen-antibody
binding reaction, which occurred on a substrate surface. After a
second wash step to remove the excess conjugate, the substrate was
coverslipped and checked for fluorescent patterns with a fluorescent
microscope. Observation of a specific fluorescent pattern on the
substrate indicated the presence of autoantibodies in the test samples.
A positive and negative control was included with each assay run.
Sera were considered positive for the presence of ANA at a starting
dilution of 1/50.
All positive sera were tested for anti-DNA antibodies by IIF on
Crithidia lucilliae as a substrate (DTS) following the same procedures
used for ANA detection.
Measurement of proteinuria. To evaluate the severity of the auto-
immune disease, proteinuria, a surrogate marker of autoimmune
nephritis, was performed. At 24, 31, and 37 wk of age, mice were
placed in metabolic cages, and urine was collected. The protein
concentration was determined by precipitation with 3% sulfosalicylic
acid in 24-h urine samples, and measurements were performed by
spectrophotometry (Spectronic, Genesys 5 Milton Roy) (15). Spec-
trophotometric measurement was carried out with a microplate reader
at 650 nm. To convert optical density values, a standard curve was
generated for each assay.
Longevity study. Mice were examined daily for signs of disease
(edema, lethargy, anorexia, piloerection, or rough hair coats) and
death.
Data analysis. The Kaplan-Meier estimator was used to estimate
the proportion of the number of mice that produced ANA and also to
estimate the proportion surviving (life span) by given time. Mice that
did not produce ANA or did not die until the end of the study were
considered censored data. Data containing uncertainty as to when
exactly an event happened are termed as censored data. Proportion
and survival curves were compared using the log rank test. Visual
inspection revealed differences between weeks 10 and 13 that might
be relevant, although not sufficiently to provide statistical evidence by
the log rank test for analysis of the whole period of study. Therefore,
the binomial test for proportions was used to analyze ANA production
in each week, independently. Statistical analysis of the anti-DNA data
was performed with the binomial test for proportions. The remainder
of the data was compared by two-way repeated-measures ANOVA
followed by the Tukey test for unbalanced groups. All data are
expressed as means SE. Statistical significance was set at P 0.05.
RESULTS
ANA and anti-DNA. Log rank data revealed that proportion
curves were similar between control and SD groups (P 
0.4185), indicating that ANA production was similar between
the groups (Fig. 1). Nonetheless, no new case was observed
between the 10th and 13th week in control mice, meaning a 0%
transition. In the SD group, however, five new cases were
found during the same time interval, resulting in 21% transi-
tion. The binomial test showed a statistical difference between
control and SD groups (0%  21%, P  0.03). No further
differences were revealed throughout the study. The produc-
tion of anti-DNA across both groups indicates that the antibody
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is spontaneously produced in this mouse strain and is not
influenced by SD.
Body weight. Analysis of the data considering the body
weights immediately before and immediately after SD (10th
vs. 12th week of life) showed a main effect of time [F(1,19) 
9.87 and P  0.005] but no effect of group or an interaction
between these factors. The post hoc analysis indicated that both
groups gained weight immediately after the period of SD (week
12) compared with week 10 (Fig. 2). Analysis of body weights
throughout the study period again revealed a main effect of
time [F(6,162)  46.17 and P  0.0001], but no interaction
between group and time. The test of Tukey showed that, for
both groups, weight gain was greater on the 16th week than on
the previous weeks of life (P  0.0001) without differences on
weeks 19, 22, 25, and 28. In the later time points, weight gain
was higher than on weeks 10, 13, and 16 (P  0.0001; Fig. 3).
Proteinuria. In terms of proteinuria, again, a main effect of
time was detected [F(2,32)  51.03 and P  0.0001]. In this
case, augmented protein excretion was observed on the 37th
week of life in both groups compared with the previous time
points (P  0.0001; Fig. 4).
Life span. The log rank test did not detect a difference
between the survival curves of the groups (P  0.1317), and
the average life span was 38 and 40 wk for the control and SD
groups, respectively (Fig. 5).
DISCUSSION
According to the present findings, SD produced an immedi-
ate and short-lasting effect, manifested by an earlier triggering
of the disease, which was reflected by more cases of positive
ANA. Nonetheless, SD did not affect the evolution or severity
of the disease, according to the proteinuria and longevity data.
Similar to other studies (7, 25), the onset and evolution of
the disease was based on the presence and amount of ANA.
This is an extremely sensitive and specific parameter, and,
contrary to human beings, it is a measurement of disease
activity.
One of the most replicable effects of SD in rats is the
progressive increase of energy expenditure, manifested by
augmented food intake and weight loss (3, 11, 16). Contrary to
what is observed in rats, SD did not produce weight loss in
NZB/NZW F1 mice. Both control and SD mice gained weight
after the manipulation compared with their pre-SD body
weight. Although we did not assess food intake, it could be
hypothesized that this distinct effect of SD is due to differences
in basal metabolism between rats and mice. The assessment of
body weight throughout the disease evolution showed that both
groups gained weight, mainly after the 22nd week of life. This
Fig. 1. Proportion curves for negative anti-nuclear antibody (ANA) percent-
ages in control (CTL; n  22) and sleep-deprived (SD; n  28) mice. Arrows
indicate the periods of SD (10th and 11th week of life).
Fig. 2. Changes in body weights during SD. Values are reported as means 
SE. *P  0.005 for comparisons with corresponding values.
Fig. 3. Body weights in CTL and SD mice. Values are reported as means 
SE. *P 0.0001, different from previous weeks; **P 0.0001, different from
weeks 10, 13, and 16. Arrows indicate periods of SD (10th and 11th weeks of
life).
Fig. 4. Time course of urinary protein excretion in CTL and SD mice. Values
are reported as means  SE. *P  0.0001, different from previous weeks.
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is likely due to a generalized edema resulting from glomeru-
lonephritis (55).
Glomerulonephritis is the most common kidney impairment
in sick animals and the most important cause of death (55), and
protein loss in the urine is the best evidence of such an
impairment. In the present study, there was a progressive loss
of protein in the urine for both groups, with a distinct increase
on the 37th week, reaching average levels of 37 mg/day, i.e., a
10-fold increase. This finding is in agreement with the litera-
ture, which indicates a massive protein loss from the eighth
month of life on (26, 55).
The average life span was similar for both groups, 38 and 40
wk for control and SD groups, respectively. This result is in
accordance with an extensive review published by Theofilo-
poulos and Dixon (55), who reported the survival rate of
several mouse strains of lupus. For NZB/NZW F1 mice, the
survival rate of females, which exhibit accelerating factors
such as high ANA titers and the presence of anti-DNA anti-
bodies, varied from 36 to 39 wk. Anti-DNA antibodies pro-
duction in the NZB/NZW F1 model occurs later in life, ap-
proximately between the fourth and fifth months of age, with
the highest prevalence on the ninth month, and rarely before
the second month of life. Even though this is seldom, some
cases can be found in the early period (55). These antibodies
are particularly important due to their nephritogenic properties.
An immunofluorescence and kidney eluate study (22) has
indicated that DNA and its antibody of the IgG class are
deposited in the kidney. Moreover, there is a significant cor-
relation between the onset of clinical symptoms and switch
from IgM to IgG, and this alteration is more pronounced in
females (38, 50).
The present results showed that SD accelerated the produc-
tion of circulating ANA. The mechanisms by which SD affects
the immune system are not completely understood, but systems
that regulate immune activity are also affected by SD, such as
the endocrine system. For instance, Everson and Crowley (12)
believe that the reduction of immune activity after SD is due to
decreased secretion of growth hormone (GH) and prolactin
(PRL). Lange and colleagues (23) observed that SD subjects
who exhibited low production of antibodies also showed low
GH and PRL levels. Therefore, PRL appears to be important
for the integrity of the immune system. Several studies using
SLE attribute to PRL a disease-triggering or -stimulating ef-
fect. There is a positive correlation between PRL concentra-
tions and the increase of anti-DNA antibodies (33). In NZB/
NZW F1 mice, PRL is immune stimulating, and modest ele-
vations of blood concentrations lead to hyper--globulinemia
and an augmented production of immune complexes, resulting
in glomerulonephritis and, ultimately, death (30). In addition,
female mice whose PRL secretion is inhibited by treatment
with bromocriptine display a postponed onset of SLE (29).
Although the literature indicates that SD reduces PRL secre-
tion, there is no report on its effect in NZB/NZW F1 mice;
nonetheless, PRL seems to be deleterious to these mice.
Some studies have indicated that sleep loss alters immune
response-related parameters, such as cytokine levels. Recently,
a study (17) showed that SD induced the secretion of inflam-
matory cytokines, including IL-1, TNF, and IL-6. As reviewed
by Kishimoto and Hirano (20), abnormal IL-6 production
results in polyclonal B cell activation and the occurrence of
autoimmune features. IL-6 has been implicated in the patho-
genesis of murine lupus, because NZB/NZW F1 mice exhibit
elevated levels of this cytokine, and their lymphocytes are also
hyperresponsive to IL-6 (1). In addition, Mihara and coworkers
(31) have shown that blockade of IL-6 receptors inhibited the
development of the disease in these mice and that the admin-
istration of recombinant IL-6 exacerbated glomerulonephritis
(44). Given that this cytokine is harmful to SLE, it is possible
to speculate that SD induced an increase in IL-6 levels in
NZB/NZW F1 mice, resulting in an earlier onset of the disease.
Another interesting finding that might explain the increased
production of ANA, which was reported by Everson (10), is
that clinical immune parameters measured after SD in rats
suggest the activation of mechanisms associated with innate
immunity and responses by B lymphocytes that are consistent
with polyclonal activation. Various reports (14, 46, 58, 60)
have shown that the acceleration of autoimmune disease is
associated to polyclonal activation of B cells. On the basis of
these studies together with the present results, we do not
believe that SD can be conceptualized as being only immuno-
suppressive condition. It is difficult to draw any firm conclu-
sions about the effects of SD on the immune system. SD
involves, to variable degrees, imposition of nonspecific stress,
which may interact with the effects attributable to sleep loss
per se. Discrepancies in literature may be related at least in part
to technical approaches and the duration of SD. It is difficult to
compare results of different deprivation protocols and dura-
tions, but it is known that the principal approaches used in the
literature (disk over water, platform, and gentle handling) in
fact induce SD. Despite these limitations, there is emerging
evidence that in rodents chronic sleep loss is detrimental rather
than acute sleep loss.
Some studies (5, 39, 59) have suggested that high levels of
life stress precede the disease outbreak or exacerbation in
patients with SLE. In an experimental model, Chida et al. (7)
demonstrated that social isolation stress exacerbates autoim-
mune disease in MRL/lpr mice. However, the potential phys-
iological mechanisms that could justify such an association
remain to be clarified. It is difficult to determine exactly which
pathway is being altered by stress. Even if it is an immune
pathway, it must be altered in a direction that will lead to
disease onset or exacerbation. Several lines of evidence sup-
port the notion that SD is a stressful stimulus. Both ACTH and
Fig. 5. Survival curves for CTL (n  22) and SD (n  28) mice. Censored
data.
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corticosterone levels are increased after SD (36, 45, 51). Thus,
it is tempting to speculate that the increased ANA production
observed after SD may be mediated by activation of the
hypothalamus-pituitary-adrenal axis. Although the exact mech-
anism of the stressor-induced increased susceptibility to the
development of an autoimmune disease is not known, some
possible explanations can be offered. As reviewed by Rabin
(40), it is possible that stress hormones alter the kinetics of
maturation of B lymphocytes so that there is a shorter window
of opportunity for B lymphocytes to become tolerant to self-
antigens. Besides, it is possible that the hormonal responses to
stress alter the interactions between the cells that are respon-
sible for the induction of tolerance of T lymphocytes, resulting
in an increased number of autoreactive T cells.
Several studies using different deprivation paradigms have
shown significant alterations in immune markers in response to
SD. Such data do not necessarily provide an indicator of how
SD impacts on immune function and how impaired is an
organism. However, recent important studies evaluated the
functional integrity of the immune system in a SD condition.
Spiegel et al. (49) and Lange et al. (23) have reported that the
response to influenza or hepatitis A vaccination may be im-
paired in individuals with chronic sleep restriction. Such data
are so relevant, inasmuch as the antibody response to vaccina-
tion constitutes a valid tool to assess the impact of SD on
adaptive immune functioning. In the same way, the present
results demonstrate clearly that the SD accelerated the timing
of autoantibody production; thus, sleep loss affects host out-
come and may be harmful to the host. This study provides
valuable information regarding how sleep loss can impact the
autoimmune disease process.
In conclusion, the present data indicate that SD is capable of
accelerating the onset of lupus in NZB/NZW F1 mice, consid-
ering ANA production as the end point. This result emphasizes
the importance of adequate sleep in SLE, in which chronic
sleep disturbances are reported. Despite the fact that SD
exerted a triggering effect, it did not alter the evolution or
severity of the disease, suggesting an acute impact. Drawing of
such a conclusion was only possible because we performed a
prolonged followup observation of SD effects on the immune
system; most studies have assessed only the acute effects,
which may be misleading in respect of the impact of sleep loss
on autoimmune diseases.
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